Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

Inclusion Criteria:

- Male or female patients, 25 years of age or older

- Diagnosis of any depressive disorder as per DSM IV criteria (except bipolar
depression and major depressive disorder with psychotic features). Note: Both
patients who are or are not being treated with bupropion or other antidepressants are
permitted into the study.

- Patients must have complained of suffering from adverse events and/or lack of effect
when switched from Wellbutrin XL® 300 mg to Budeprion XL™ 300 mg.

- BMI (kg/m2) Greater than or equal to 19 and less than or equal to 34.

- No clinically significant abnormal laboratory values

- No clinically significant findings in a 12-lead electrocardiogram (ECG)

- No clinically significant findings in vital signs measurements.

- Be informed of the nature of the study and give written consent prior to receiving
any study procedure.

Exclusion Criteria

- Carcinoma within the last 5 years. Note: Patients with basal or squamous cell
carcinoma may be permitted into the study on a case by case basis.

- A history of epilepsy or risk for seizures.

- A previous or current diagnosis of bipolar depression.

- A current diagnosis of major depressive episode with psychotic features. Note:
Subjects with previous diagnosis of major depressive episode with psychotic features
may be included at the investigator's discretion.

- A previous or current diagnosis of an eating disorder (e.g. bulimia, anorexia
nervosa).

- A lifetime history of schizophrenia or schizo-affective disorder.

- Significant disease(s) or clinically significant finding(s) in a physical examination
determined by an investigator to pose a health concern to the patient while on study.

- Presence of clinically significant gastrointestinal disease and/or surgery (e.g.
gastric bypass surgery) or history of malabsorption within the last year.

- Known history or presence of an allergic sensitivity to bupropion and/or any other
drug substances with similar activity.

- Expected changes in use of permitted concomitant medication that will be continued
throughout the study.

- Undergoing abrupt discontinuation of sedatives (including benzodiazepines).

- Use of monoamine oxidase inhibitors (MAOI) within 2 weeks prior to study admission.

- Taking medications that interact with CYP2B6 within 30 days prior to Day 1 dosing.

- Taking levodopa, amantadine, drugs that lower seizure threshold (e.g. theophylline,
systemic steroids, antipsychotics), and/or on nicotine replacement therapy.

- History of alcohol or drug-dependence by DSM IV criteria within 6 months prior to
study admission.

- Positive test results for:

- HIV

- Hepatitis B surface antigen or Hepatitis C antibody

- Urine drugs of abuse (i.e. marijuana, amphetamines, barbiturates, cocaine,
opiates, methadone, and phencyclidine) Note: any positive test result(s) for
benzodiazepine(s) must be assessed by the investigator to determine whether the
patient should be excluded from this study.

- Serum hCG consistent with pregnancy (females only).

- On a special diet within 30 days prior to study admission (e.g. liquid, protein, raw
food diet).

- Difficulty fasting or consuming standard meals.

- Participated in another clinical trial or received an investigational product within
45 days prior to Day 1 drug administration.

- Donation or loss of whole blood:

- Less than or equal to 499 mL within 30 days prior to dosing

- Greater than or equal to 500 mL within 56 days prior to dosing Note: blood taken
for routine medical evaluations totaling less than 50 mL will be permitted.

- Females who have discontinued the use of:

- implanted, intrauterine, or injected hormonal contraceptives within 6 months
prior to Day 1 drug administration, OR

- oral, intravaginal, or patch hormonal contraceptives within 1 month prior to Day
1 drug administration

- Females who started taking:

- implanted or intrauterine hormonal contraceptives less than 6 months prior to
Day 1 drug administration, OR

- oral, intravaginal, patch, or injected hormonal contraceptives less than 3
months prior to Day 1 drug administration.

- Females who are pregnant, lactating, or likely to become pregnant during the study.

- Have had a newly applied tattoo or body piercing within 30 days prior to study
admission.

- Does not tolerate venipuncture.

- Unable or unwilling to provide informed consent.